379 related articles for article (PubMed ID: 32368414)
1. Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy.
Al Abbar A; Ngai SC; Nograles N; Alhaji SY; Abdullah S
Biores Open Access; 2020; 9(1):121-136. PubMed ID: 32368414
[TBL] [Abstract][Full Text] [Related]
2. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
3. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
4. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
Omole AE; Fakoya AOJ
PeerJ; 2018; 6():e4370. PubMed ID: 29770269
[TBL] [Abstract][Full Text] [Related]
5. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
6. Human iPSCs and Genome Editing Technologies for Precision Cardiovascular Tissue Engineering.
Gähwiler EKN; Motta SE; Martin M; Nugraha B; Hoerstrup SP; Emmert MY
Front Cell Dev Biol; 2021; 9():639699. PubMed ID: 34262897
[TBL] [Abstract][Full Text] [Related]
7. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
8. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Genome Engineering in Human Pluripotent Stem Cells.
Merkert S; Martin U
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
Kim EJ; Kang KH; Ju JH
Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
[TBL] [Abstract][Full Text] [Related]
11. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
[TBL] [Abstract][Full Text] [Related]
12. A Broad Overview and Review of CRISPR-Cas Technology and Stem Cells.
Waddington SN; Privolizzi R; Karda R; O'Neill HC
Curr Stem Cell Rep; 2016; 2(1):9-20. PubMed ID: 27398291
[TBL] [Abstract][Full Text] [Related]
13. CRISPR activation enables high-fidelity reprogramming into human pluripotent stem cells.
Sokka J; Yoshihara M; Kvist J; Laiho L; Warren A; Stadelmann C; Jouhilahti EM; Kilpinen H; Balboa D; Katayama S; Kyttälä A; Kere J; Otonkoski T; Weltner J; Trokovic R
Stem Cell Reports; 2022 Feb; 17(2):413-426. PubMed ID: 35063129
[TBL] [Abstract][Full Text] [Related]
14. A Prospective Treatment Option for Lysosomal Storage Diseases: CRISPR/Cas9 Gene Editing Technology for Mutation Correction in Induced Pluripotent Stem Cells.
Christensen CL; Choy FYM
Diseases; 2017 Feb; 5(1):. PubMed ID: 28933359
[TBL] [Abstract][Full Text] [Related]
15. Combining Induced Pluripotent Stem Cells and Genome Editing Technologies for Clinical Applications.
Chang CY; Ting HC; Su HL; Jeng JR
Cell Transplant; 2018 Mar; 27(3):379-392. PubMed ID: 29806481
[TBL] [Abstract][Full Text] [Related]
16. Direct cell reprogramming for tissue engineering and regenerative medicine.
Grath A; Dai G
J Biol Eng; 2019; 13():14. PubMed ID: 30805026
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
18. Tissue-Restricted Stem Cells as Starting Cell Source for Efficient Generation of Pluripotent Stem Cells: An Overview.
Sundaravadivelu PK; Raina K; Thool M; Ray A; Joshi JM; Kaveeshwar V; Sudhagar S; Lenka N; Thummer RP
Adv Exp Med Biol; 2022; 1376():151-180. PubMed ID: 34611861
[TBL] [Abstract][Full Text] [Related]
19. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
20. Generation of an Induced Pluripotent Stem Cell Line with the Constitutive EGFP Reporter.
Butterfield KT; McGrath PS; Han CM; Kogut I; Bilousova G
Methods Mol Biol; 2020; 2155():11-21. PubMed ID: 32474864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
